[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-341013-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-341013-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","gender-oncology-recommendations-and-consensus-of-the-italian-association-of-medical-oncology-aiom","Gender oncology - recommendations and consensus of the Italian Association of Medical Oncology (AIOM)","","Gender oncology recommendations and consensus document developed by an AIOM-approved working group addresses gender differences in cancer epidemiology, treatment response, and toxicity, including considerations for sexual and gender minority populations. Using a RAND/UCLA consensus conference approach, the panel evaluated statements drawn from scientific literature and expert good practice points across healthcare organization, therapy, host factors, cancer biology, and communication/social interventions, supplemented with successful case studies. The results generated 50 extracted recommendations plus additional panel statements, forming a basis for research and standardized clinical care.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/gender-oncology-recommendations-and-consensus-of-the-italian-association-of-medical-oncology-aiom/341013/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/gender-oncology-recommendations-and-consensus-of-the-italian-association-of-medical-oncology-aiom/341013.png","ImageObject",300,407,{"name":42,"@type":43},"Lucas Martin","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-08","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",9,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What is the main purpose of the AIOM gender oncology consensus document?","Question",{"text":63,"@type":64},"To evaluate available scientific evidence on gender oncology and propose standard criteria for research and clinical care that account for gender.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How was the consensus developed in this document?",{"text":68,"@type":64},"An AIOM-approved working group used the RAND/UCLA variant ‘consensus conference’ method to evaluate literature-based statements and expert good practice points across predefined topic areas.",{"name":70,"@type":61,"acceptedAnswer":71},"What topics did the panel consider when forming recommendations?",{"text":72,"@type":64},"Healthcare organisation, therapy, host factors, cancer biology, and communication/social interventions.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},341013,1790197322,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},8796095360427,"https://ap-avatar.wpscdn.com/davatar_994ba38a5ba835b3df7d355c54d3ed8d","ORIGINAL ARTICLE  \nGender oncology: recommendations and consensus of the Italian Association of Medical Oncology (AIOM)  \nR. Berardi1, 2 , 3􀀁, F. Rossi1, R. Papa4, M. Appetecchia5, G. Baggio6, M. Bianchini5, T. Mazzei7, A. Maria Moretti8, 9,  \nE. Ortona10, F. Pietrantonio11, V. Tarantino1, T. Vavalà12, 13 , 14 & S. Cinieri15, 16  \n1Medical Oncology, Polytechnic University of Marche Region, Ancona; 2Medical Oncology, AOU Marche, Ancona; 3Treasurer AIOM (Italian Association of Medical Oncology); 4Quality, Risk Management and Health Technology Innovation Unit, Department of Staff, AOU Marche, Ancona; 5Oncological Endocrinology Unit, IRCCS Regina Elena National Cancer Institute, Rome; 6President of the Italian Research Center for Gender Health and Medicine, Chair of Gender Medicine 2012-2017, University of Padua, Padua; 7Department of Pharmacology, University of Florence, Florence; 8National President of the Scientiﬁc Society GISeG (Italian Group Health and Gender); 9President of the International Society IGM (International Gender Medicine); 10Head-Center for Gender-speciﬁc Medicine, Italian National Institute of Health, Rome; 11Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan; 12SC of Oncology 1U, Department of Oncology, AOU Città della Salute e della Scienza, Torino; 13AIOM (Italian Association of Medical Oncology); 14GISeG (Italian Group Health and Gender); 15Medical Oncology and Breast Unit, Perrino Hospital, Brindisi; 16President of AIOM Foundation (Italian Association of Medical Oncology), Italy  \nAvailable online 23 February 2024  \nBackground: Following the development of gender medicine in the past 20 years, more recently in the ﬁeld of oncology an increasing amount of evidence suggests gender differences in the epidemiology of cancers, as well as in the response and toxicity associated with therapies. In a gender approach, critical issues related to sexual and gender minority (SGM) populations must also be considered.  \nMaterials and methods: A working group of opinion leaders approved by the Italian Association of Medical Oncology (AIOM) has been set up with the aim of drafting a shared document on gender oncology. Through the ‘consensus conference’ method of the RAND/University of California Los Angeles (UCLA) variant, the members of the group evaluated statements partly from the scientiﬁc literature and partly produced by the experts themselves [good practice points (GPPs)], on the following topics: (i) Healthcare organisation, (ii) Therapy, (iii) Host factors, (iv) Cancer biology, and (v) Communication and social interventions. Finally, in support of each speciﬁc topic, they considered it appropriate to present some successful case studies.  \nResults: A total of 42 articles met the inclusion criteria, from which 50 recommendations were extracted. Panel participants were given the opportunity to propose additional evidence from studies not included in the research results, from which 32 statements were extracted, and to make recommendations not derived from literature such as GPPs, four of which have been developed. After an evaluation of relevance by the panel, it was found that 81 recommendations scored >7, while 3 scored between 4 and 6 .9, and 2 scored below 4 .  \nConclusions: This consensus and the document compiled thereafter represent an attempt to evaluate the available scientiﬁc evidence on the theme of gender oncology and to suggest standard criteria both for scientiﬁc research and for the care of patients in clinical practice that should take gender into account.  \nKey words: gender oncology, cancer, epidemiology, outcome and toxicity, anticancer therapies  \nINTRODUCTION  \nIn medicine, pharmaceutical clinical trials, and scientiﬁc research, the study of gender differences is a recent development that represents a milestone of great importance in the progress of science.  \n*Correspondence to: Prof. Rossana Berardi, Medical Oncology, Polytechnic University of Marche Region, An","cbCaivxBLXvdw4Ei","https://ap.wps.com/l/cbCaivxBLXvdw4Ei","pdf",523434,11,"English","# Background\n# Materials and methods\n# Results\n# Conclusions\n# Introduction","[{\"question\":\"What is the main purpose of the AIOM gender oncology consensus document?\",\"answer\":\"To evaluate available scientific evidence on gender oncology and propose standard criteria for research and clinical care that account for gender.\"},{\"question\":\"How was the consensus developed in this document?\",\"answer\":\"An AIOM-approved working group used the RAND/UCLA variant ‘consensus conference’ method to evaluate literature-based statements and expert good practice points across predefined topic areas.\"},{\"question\":\"What topics did the panel consider when forming recommendations?\",\"answer\":\"Healthcare organisation, therapy, host factors, cancer biology, and communication/social interventions.\"}]","Gender oncology - recommendations and consensus of the Italian Association of Medical Oncology (AIOM) | PDF",1790039924,28,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/438ada9bf8ff7fdddffdeb1fcd23623a.webp",983,1269,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/245a902f7205495c0d26f5432476c8ca.webp",982,1268,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c68e6123d024bc8d8454eadcfff69ca8.webp",981,1266,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4dc149acf4d07ff7fd4da24329ba13e5.webp",980,1265]